Study Shows Abiraterone Acetate is Useful Even in Most Aggressive Prostate Cancers; University of Colorado Cancer Center
In 1,048 prostate cancer patients previously treated with docetaxel and 996 metastatic, castration-resistant patients, treatment with the androgen-lowering drug abiraterone acetate led to longer overall disease control, even when a very high Gleason score indicated especially aggressive cancer. Results recently published in the Annals of Oncology show that for patients with Gleason score greater than 8, post-docetaxel treatment with abiraterone extended progression-free survival from 5.5 months ...
Source: National Comprehensive Cancer Network - Category: Cancer & Oncology Source Type: news
More News: Abiraterone Acetate | Cancer | Cancer & Oncology | Docetaxel | Prostate Cancer | Study | Taxotere